Clinical Trial Update: Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Fc-Optimized Anti-CD19 antibody MOR00208 in Non-Hodgkin Lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• MOR00208

Snippet

Sponsor: MorphoSys AG | Conditions: Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-07